Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCLD-CoV19-1 OMI
- Development stage
- Phase 3
- Lead developer
- Cellid
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AdCLD-CoV19-1 OMI is a non-replicating recombinant adenoviral vector vaccine developed for the prevention of COVID-19, specifically targeting the Omicron variant. It utilizes an adenovirus type 5/35 (Ad5/35) platform to deliver the gene encoding the spike protein of SARS-CoV-2, particularly from Omicron subvariants such as BA.1. The vaccine is administered intramuscularly and is being evaluated as a booster in healthy adults. Its mechanism involves inducing an immune response against the SARS-CoV-2 spike protein to confer protection against COVID-19 infection[4][5][8]. The developer and manufacturer is Cellid, a South Korean biotechnology company[4][5][8]. As of April 2025, it is in Phase 3 clinical trials in multiple countries including Korea and the Philippines for use as a preventive booster vaccine against COVID-19[4][5][8].
- Other names
- AdCLD-CoV19(Cellid)
02
Targets
Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)SARS-CoV-2 Omicron spike protein non-RBD epitopes
Beyond the preview
Go deeper on AdCLD-CoV19-1 OMI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCLD-CoV19-1 OMI.